Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis

Wenting Xie1†, Fugui Su2†, Guizhong Wang3†, Zichong Peng1†, Yaomin Xu1, Yi Zhang1, Ningning Xu1, Kajian Hou4, Zhuping Hu5, Yan Chen6* and Rongping Chen1*

1Department of Endocrinology, Zhujiang Hospital, Southern Medical University/The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China, 2Department of Endocrinology, Suixi Country People’s Hospital, Guangzhou, China, 3Department of Critical Care Medicine, Zhujiang Hospital, Southern Medical University/The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China, 4Department of Endocrine and Metabolic Diseases, Longhu Hospital, The First Affiliated Hospital of Medical College of Shantou University, Shantou, Guangdong, China, 5Department of Endocrinology, Wengyuan Country People’s Hospital, Shaoguan, China, 6Department of Reproductive Medicine, Center of Maternal and Child Health Hospital of Shaoguan City, Shaoguan, Guangdong, China

Background: Insulin secretory agents are commonly used to treat type 2 diabetes. However, traditional insulin secretory agents such as sulfonylureas and glinides have side effects of hypoglycemia. In recent years, researchers have discovered that berberine can inhibit the voltage-gated K⁺ channels of pancreatic β cell membrane and promote insulin secretion without causing hypoglycemia, because the glucose-lowering effects of berberine are only under hyperglycemic conditions or in a high-glucose-dependent manner. In order to shed light on the glucose-lowering effects of berberine in type 2 diabetes with different baseline fasting plasma glucose (FPG) and glycosylated hemoglobin (HbA1c), we conducted a meta-analysis of randomized controlled trials.

Methods: We searched eight databases, which included PubMed, EMBASE, Web of Science, the Cochrane Library, and the Chinese databases such as Sino-Med, China National Knowledge Infrastructure (CNKI), Wanfang Database, and VIP Database for Chinese Technical Periodicals, for randomized controlled trials, with berberine as the intervention and patients with type 2 diabetes mellitus as subjects, published up until November 2021. We analyzed the glucose-lowering effects of berberine, including its effects on FPG, HbA1c and 2-h plasma blood glucose (2hPBG), by calculating weighted mean differences (WMD) and 95% confidence interval (CI). To assess the safety of berberine, we analyzed the incidence of total adverse events and hypoglycemia by calculating relative risk (RR) and 95% CI.

Results: Thirty-seven studies involving 3,048 patients were included in the meta-analysis. The results showed that berberine could reduce FPG (WMD = -0.82 mmol/L, 95% CI (-0.95, -0.70)), HbA1c (WMD = -0.63%, 95% CI (-0.72, -0.53)), and 2hPBG (WMD = -1.16 mmol/L, 95% CI (-1.36, -0.96)), with all results...
being statistically significant. Subgroup analyses revealed that the glucose-lowering effect of berberine was associated with baseline mean FPG and HbA1c in type 2 diabetes. In addition, berberine alone or in combination with oral hypoglycemic agents (OHAs) in the treatment of T2DM did not significantly increase the incidence of total adverse events (RR = 0.73, 95% CI (0.55, 0.97), p = 0.03) and the risk of hypoglycemia (RR = 0.48, 95% CI (0.21, 1.08), p = 0.08).

**Conclusion:** Berberine has a glucose-lowering effect, which is related to the baseline FPG and HbA1c levels of patients. Treatment with berberine may be safe since it does not increase the incidence of total adverse events and the risk of hypoglycemia.

**Systematic Review Registration:** https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=292975, identifier CRD42021292975.

**KEYWORDS**

berberine, type 2 diabetes, meta-analysis, safety, glucose-lowering effect

---

**1 Introduction**

According to the International Diabetes Federation (IDF) Diabetes Atlas, 10th edition, the global prevalence of diabetes among people between the ages of 20 and 79 years in 2021 was 10.5%, which is predicted to rise to 12.2% in 2045. Health expenditures associated with diabetes in the world in 2021 were about $966 billion, which are expected to increase to $1,054 billion by 2045 (Sun H. et al., 2022). There is growing evidence that chronic inflammation and some metabolic diseases are associated with insulin resistance, type 2 diabetes mellitus (T2DM) and systemic diabetic complications (Bray et al., 2021; Leite et al., 2021).

OADs, oral hypoglycemic agents (OHAs) are commonly used in the treatment of T2DM, which can decrease blood glucose levels effectively. They mainly include the following categories: Sulfonylureas, glinides, biguanides, thiazolidinediones, α-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) agonists and sodium-glucose transporter-2 (SGLT2) inhibitors. Increasing insulin secretion is regarded as one of the important strategies of treating T2DM. Drugs such as sulfonylureas and glinides inhibit the adenosine triphosphate (ATP)-sensitive potassium channel (KATP) in pancreatic β cells, leading to the slow depolarization of pancreatic islet β-cell membrane and the inward flow of calcium ions, which in turn stimulates the release of insulin (Nagy et al., 2018). However, it is worth noting that these two classes of drugs may lead to severe hypoglycemia, which can cause 4 to 10 percent of disease-related deaths (Chang et al., 2020). Insulin and insulin secretagogues have been reported to increase the risk of developing breast, liver, pancreatic, and colorectal cancer (Tokajuk et al., 2015). Considering the impact of the adverse reactions potentially resulting from OHAs, many studies have investigated the relationship between T2DM and berberine (BBR).

In China, a classic Chinese herbal formula that includes BBR is a good remedy for diabetes. BBR is an isoquinoline alkaloid that is extracted from traditional Chinese medicines such as Cortex phellodendri (Huangbai) and Rhizoma coptidis (Huanglian) (Wu et al., 2020). Studies have shown that BBR has hyperglycemia-dependent glucose-lowering effects. Because BBR, as an insulinotropic agent, directly binds to KCNH6 potassium channels and reduces KCNH6 currents by accelerating channel closure, which prolongs the high glucose-dependent cell membrane depolarization and ultimately promotes insulin secretion (Zhao et al., 2021). The pharmacological mechanism of BBR implies that it acts as a glucose-lowering agent at high blood glucose levels, but this effect is not apparent in people with normal blood glucose, which greatly reduces the probability of hypoglycemia and provides a significant therapeutic advantage over OHAs. Recent meta-analyses (Dong et al., 2012; Lan et al., 2015; Liang et al., 2019; Guo et al., 2021) have all shown that BBR is effective in the treatment of T2DM. However, the latest two meta-analyses (Liang et al., 2019; Guo et al., 2021) showed obvious heterogeneity after including more literature than the earliest two meta-analyses (Dong et al., 2012; Lan et al., 2015), especially when including the literature on fasting plasma glucose (FPG). After a subgroup analysis, the problem of obvious heterogeneity still existed, which questioned the effectiveness of BBR. We believe that the obvious heterogeneity in the previous meta-analyses may stem from differences in the baseline mean FPG and glycosylated hemoglobin (HbA1c) of the patients they included.

Consequently, to illustrate the glucose-lowering effects of BBR in T2DM patients with different baseline mean FPG and HbA1c, which could provide references and recommendations for the clinical use of BBR, we systematically searched and analyzed all randomized controlled trials (RCTs) to perform a systematic literature review and a meta-analysis.
2 Methods

The review protocol was registered on PROSPERO (No: CRD42021292975).

2.1 Search strategy and study selection

Two investigators independently searched the following databases from study inception to November 2021: PubMed, EMBASE, Web of Science, the Cochrane Library, and the Chinese databases: Sino-Med, China National Knowledge Infrastructure (CNKI), Wanfang Database and VIP Database for Chinese Technical Periodicals. The search terms were used as follows [“Berberine” OR “Huangliansu” OR “Xiaobojian”] AND [“diabetes” OR “type 2 diabetes” OR “type 2 diabetes mellitus” OR “type II diabetes” OR “type II diabetes mellitus” OR “T2DM” OR “DM” OR “non-insulin-dependent diabetes mellitus”]. There was no restrictions on publication language or publication date, and the reference lists of included literature and related meta-analyses were manually searched to meet higher recall and precision ratio. PICOS of included studies was shown in Table 1. All articles were selected preliminarily by the title and abstract.

For those that could not be judged by title or abstract, we read the full text.

2.2 Data extraction and quality assessment

Two researchers independently extracted and cross-checked the information from selected articles, which included the published information, study design, patient information and the outcomes including FPG, 2hPBG, HbA1c, the incidence of total adverse events and hypoglycemia. The Cochrane Risk of Bias Tool was used to evaluate the quality of the included literature. The items included random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias) and other bias. Each item was categorized as low/unclear/high risk of bias.

2.3 Data synthesis and analysis

The continuous variables were presented by calculating weighted mean differences (WMD) and 95% confidence

---

TABLE 1 The PICOS of our study.

| PICOS terms                     | Details                                                                                                                                 |
|--------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| Population                     | T2DM patients of all ages and genders were included in our study. The criteria is base on Chinese Guidelines for the prevention and treatment of Type 2 Diabetes Mellitus or 1999 World Health Organization criteria. |
| Interventions & Comparators    | The Interventions group included the patients who were treated with berberine alone or in combination with other OHAs. The Comparators group included the patients who were treated with blank, placebo, lifestyle intervention or OHAs. In conclusion, only two situations fitted our purpose of exploring the effect of berberine, which are berberine vs. blank/placebo/lifestyle intervention and berberine combined with other OHAs vs. OHAs. If the study design didn’t include these two combinations, the study should be excluded. For example, 1) Study A: berberine vs. placebo, the ‘berberine’ group is considered as intervention group, the ‘placebo’ group is considered as comparator group; 2) Study B: berberine + metformin vs. berberine vs. metformin, the ‘berberine + metformin’ group is considered as intervention group, the ‘metformin’ group is considered as comparator group; 3) Study C: berberine vs. sulfonylureas, excluded; 4) Study D: berberine + metformin vs. berberine, excluded. |
| Outcomes                       | Primary Fastiging Plasma Glucose (FPG). 2-hour postprandial blood glucose (2hPBG), Glycated Hemoglobin (HbA1c), the incidence of total adverse events and hypoglycemia. |
| Study design                    | The studies were included if they met the following criteria: 1) Met the criteria above in this table; 2) Reported the baseline of FPG, 2hPBG or HbA1c and also reported them as an outcome indicator; 3) Randomized controlled trials. The exclusion criteria were: 1) the exact means and standard deviations of FPG, 2hPBG, HbA1c before and after treatment were not reported completely in article; 2) T2DM with other chronic diseases or diabetic complications; 3) The animal experiments; 4) Non-RCT experiments, conference articles, reviews and duplicate publications |
interval (CI), whereas the risk ratio (RR) and its 95% CI were used for dichotomous outcomes. To assess the statistical heterogeneity among the included studies, we used I² statistics and Cochrane’s Q test. When $p > 0.1$ in Cochrane’s Q test or I² statistics $< 50\%$, a fixed effect model was chosen. When $p < 0.1$ or I² statistics $> 50\%$, it showed that heterogeneity was significant, and we performed subgroup analyses according to the basis of patients’ FPG and HbA1c levels before treatment to investigate the source of heterogeneity. If the heterogeneity still existed, we used random effect model to explain the results cautiously. In order to test the stability of the research, sensitivity analyses were conducted to assess changes in FPG, the primary outcome, by excluding reports of apparently poor quality and eliminating studies with too short treatment duration ($\leq 3$w). Publication bias was evaluated using a funnel plot and Egger’s Test. All statistical analyses were performed using Revman version 5.3 and Stata version 12.0.

2.4 The quality of evidence

We rated the quality of the evidences of our meta-analysis with the grading of recommendations, assessment, development
and evaluation (GRADE) approach, using the online tool named GRADEpro GDT (https://gdt.gradepro.org). Ratings were based on the GRADE handbook (https://gdt.gradepro.org/app/handbook/handbook.html).

3 Results

3.1 Literature search

A total of 4,208 publications were initially retrieved by literature search. After excluding duplicate references and carefully reading the titles, abstracts, and the full texts, 37 randomized controlled trials (Liu, 2004; Cao, 2007; Li and Liu, 2007; You and Liu, 2007; Li, 2008; Liu and Hu, 2008; Wang, 2008; Xu, 2008; Yang, 2008; Zhang et al., 2008; Sheng, 2009; Zhu et al., 2009; Gu et al., 2010; Yang, 2010; Ye, 2010; Xiang et al., 2011; Yin, 2011; Xue et al., 2012; Zhang and Yuan, 2012; Liu, 2013; Li, 2014; Yao and Xie, 2015; Zhu et al., 2015; Lang and Zhu, 2016; Li, 2016; Dong et al., 2017; Sun, 2017; Zhang, 2017; Zhang and Chen, 2017; Fan et al., 2018; Rashidi et al., 2018; Jiang and Wang, 2019; Yang et al., 2020; Yu, 2020; Zhu et al., 2020; Wei and Deng, 2021; Ye, 2021) were finally included in the quantitative meta-analysis. Detailed steps were shown in Figure 1.

3.2 Description of included studies

After systematic selection and evaluation, 37 articles were finally included, as shown in Table 2. Three articles (Zhang et al., 2008; Gu et al., 2010; Rashidi et al., 2018) were English studies, while the rest were published in Chinese, all of which were journal articles. Of these studies, one (Rashidi et al., 2018) was conducted in Iran and the others were carried out in China, enrolling 3,048 patients with T2DM in total. Additionally, all studies were RCTs: 27 studies were conducted in a dual-arm parallel group design, and the other ten studies were divided into three groups.

Of these 37 studies, seven studies (Wang, 2008; Zhang et al., 2008; Gu et al., 2010; Xiang et al., 2011; Li, 2014; Lang and Zhu, 2016; Rashidi et al., 2018) compared BBR with placebo or no drug, while 20 studies (Liu, 2004; You and Liu, 2007; Liu and Hu, 2008; Xu, 2008; Sheng, 2009; Yang, 2010; Ye, 2010; Yin, 2011; Zhang and Yuan, 2012; Liu, 2013; Yao and Xie, 2015; Zhu et al., 2015; Dong et al., 2017; Sun, 2017; Fan et al., 2018; Jiang and Wang, 2019; Yang et al., 2020; Yu, 2020; Zhu et al., 2020; Wei and Deng, 2021) made a comparison between a co-intervention of BBR and one or two types of OHAs and a control of the same OHAs. In addition, ten studies (Cao, 2007; Li and Liu, 2007; Li, 2008; Yang, 2008; Zhu et al., 2009; Xue et al., 2012; Li, 2016; Zhang, 2017; Zhang and Chen, 2017; Ye, 2021) made comparisons among a co-intervention of BBR and one type of OHAs, a control of the same OHAs, a control of BBR or no drug. Among these 37 studies, five studies (Zhu et al., 2009; Xue et al., 2012; Zhang, 2017; Zhang and Chen, 2017; Ye, 2021) retained the original dosage of sulfonylureas but did not specify dose. A study (You and Liu, 2007) did not explain the types and doses of OHAs. Another study (Zhu et al., 2020) did not specify the doses of OHAs. The OHAs used in the control group included metformin, sulfonylureas (including glipizide, gliclazide, and glimepiride), thiazolidinediones (including pioglitazone), and acarbose.

Study periods ranged anywhere from 14 days to 6 months, with three trials of 180 days, 16 trials lasted for 90 days (3m), ten trials lasted for 84 days (12w), and five trials lasted for 21–60 days (3w-2m). A trial (Liu, 2004) lasted for 14 days (2w), and another trial (Liu, 2013) lasted for 112 days (16w).

The most common dose of BBR ranged 0.9–2.4 g/d. In two trials (Yang, 2010; Zhang and Yuan, 2012), the dosage of BBR ranged from 1.5 to 2.4 g/d; in three trials (Zhang, 2017; Zhang and Chen, 2017; Ye, 2021), patients received 9.0 g/d; in a study (Sun, 2017), patients received 0.09 g/d; in a study (Zhu et al., 2015), patients received 0.3 g/d; and in the remaining 30 trials, the dose of BBR ranged 0.9–1.5 g/d.

In Table 3 and 4, according to the inclusion criteria, the control group included other OHAs, placebo, or lifestyle intervention group, while the experimental group included BBR or the combined use of BBR and the interventions in the control group. For example, in a study (Li, 2014), the placebo group was the control group and the BBR group was the experimental group; on the other hand, in a study published by Li in 2008 (Li, 2008), the metformin group was the control group and the BBR group combined with metformin group was the experimental group. Table 3 was organized according to baseline mean FPG and Table 4 ranked according to baseline mean HbA1c (the mean was calculated as the sum of the control group and experimental group divided by two). The mean of FPG was included in each of the 37 trials, and four subgroups were divided according to baseline mean FPG: less than 7.5 mmol/L, 7.5–8.8 mmol/L, 8.8–10.0 mmol/L, and greater than or equal to 10.0 mmol/L; The mean of HbA1c was included in 31 of 37 trials, and two subgroups were divided according to baseline mean HbA1c: less than 9.0% and greater than or equal to 9.0%. Detailed contents were shown in Table 3 and Table 4.

3.3 Risk of bias

Most studies included in the meta-analysis was of moderate quality, mainly due to poor reporting of allocation concealment and blinding of participants and personnel. Among the 37 RCTs included in the meta-analysis, 12 studies provided definite information on random sequence generation. Three trials described allocation concealment, and six trials exhibited blinding of participants and personnel. In addition,
TABLE 2 Characteristics of included studies in the meta-analysis.

| Study      | Year | Region | Drug | Dose (mg, min-max/d) | Lifestyle Intervention | Mean Age (SD) | Size | Length of Trial | Efficacy |
|------------|------|--------|------|----------------------|-----------------------|---------------|------|-----------------|----------|
| Li         | 2012 | China  | BBR  | 1500 tid             | Yes                   | 45.5 (2.5)    | 60   | 6m              | FPG, 2hPBG, HbA1c |
| Wang       | 2008 | China  | BBR  | 900 tid              | Yes                   | 47.74 (7.39)  | 31   | 12w             | FPG, 2hPBG, HbA1c |
| Lang       | 2016 | China  | BBR  | 1500 tid             | Yes                   | 46.3 (4.7)    | 50   | 3m              | FPG, 2hPBG, HbA1c |
| Xiang      | 2011 | China  | BBR  | 1200 tid             | Yes                   | Unknown       | 20   | 12w             | FPG, 2hPBG, HbA1c |
| Gu and Zhang | 2010 | China  | BBR  | 1000 qd              | Unknown               | 51 (9)        | 30   | 3m              | FPG, 2hPBG, HbA1c |
| Rashidi    | 2018 | Iran   | BBR  | 1000 bid             | Yes                   | 50.18 (4.22)  | 42   | 4w              | FPG, 2hPBG |
| Zhang and Li | 2008 | China  | BBR  | 1000 bid             | Unknown               | 51 (10)       | 57   | 3m              | FPG, 2hPBG, HbA1c |
| You and Liu | 2007 | China  | OHAs a | Unknown               | Yes                   | Unknown       | 19   | 3w              | FPG |
| Sun        | 2017 | China  | MET  | 1500 tid             | Yes                   | 53.07 (8.51)  | 30   | 8w              | FPG, 2hPBG, HbA1c |
| Liu        | 2004 | China  | MET  | 1500 tid             | Yes                   | 52.00 (9.81)  | 30   | 8w              | FPG, 2hPBG, HbA1c |
| Dong       | 2017 | China  | MET  | 1500 tid             | Yes                   | 51.34 (4.43)  | 49   | 12w             | FPG, 2hPBG, HbA1c |
| Fan        | 2018 | China  | MET  | 1500 tid             | Yes                   | 52.71 (7.89)  | 40   | 3m              | FPG, 2hPBG, HbA1c |
| Liu        | 2013 | China  | MET  | 1000–2000 tid        | Yes                   | 47.5 (6.5)    | 32   | 16w             | FPG, 2hPBG, HbA1c |
| Jiang      | 2019 | China  | MET  | 1500 tid             | Yes                   | 62.76 (4.59)  | 51   | 12w             | FPG, 2hPBG, HbA1c |
| Zhang and Yuan | 2012 | China  | MET  | 1500 tid             | Yes                   | 63.19 (4.82)  | 51   | 12w             | FPG, 2hPBG, HbA1c |
| Yun        | 2011 | China  | MET  | 1500 tid             | Yes                   | Unknown       | 30   | 6m              | FPG, 2hPBG, HbA1c |
| Yang       | 2020 | China  | MET  | 2000 bid             | Yes                   | 49.7 (7.4)    | 96   | 3m              | FPG, 2hPBG, HbA1c |
| Yu         | 2020 | China  | MET+placebo         | 1000–2000 tid         | Yes                   | 42.58 (6.44)  | 52   | 24w             | FPG, 2hPBG, HbA1c |
| Yang       | 2008 | China  | MET  | 750–1500 tid         | Yes                   | 53.6 (12.9)   | 30   | 3m              | FPG, 2hPBG, HbA1c |

(Continued on following page)
### TABLE 2 (Continued) Characteristics of included studies in the meta-analysis.

| Study   | Year | Region | Drug      | Dose (mg, min-max/d) | Lifestyle Intervention | Mean Age (SD) | Size | Length of Trial | Efficacy |
|---------|------|--------|-----------|----------------------|------------------------|---------------|------|-----------------|----------|
| Cao     | 2007 | China  | MET       | 1500 tid            | Yes                    | 53.6 (12.9)  | 30   | 3m              | FPG, 2hPBG, HbA1c |
|         |      |        | BBR       | 1500 tid            |                        | 55.3 (11.5)  | 30   |                 |          |
|         |      |        | no drug   | \             |                        | 55.4 (10.7)  | 30   |                 |          |
| Li      | 2008 | China  | MET       | 1500 tid           | Yes                    | 61 (12)      | 17   | 12w             | FPG, 2hPBG |
|         |      |        | BBR       | 900 tid            |                        |              | 17   |                 |          |
|         |      |        | MET+BBR   | 1500 + 900 tid/tid |                        | 55.98 (8.24) | 30   | 12w             | FPG, 2hPBG, HbA1c |
| Li*     | 2016 | China  | MET       | 750 tid            | Yes                    | 55.4 (10.7)  | 30   |                 |          |
|         |      |        | BBR       | 750 tid            |                        |              | 30   |                 |          |
| Zhu*    | 2009 | China  | MET       | 150 tid            | Yes                    | 42 (12)      | 50   | 3m              | FPG, 2hPBG, HbA1c |
|         |      |        | BBR       | 150 + 1500 tid/tid |                        |              | 55   |                 |          |
| Xue*    | 2012 | China  | MET       | 750 tid            | Yes                    | 54 (11)      | 45   | 12w             | FPG, 2hPBG, HbA1c |
|         |      |        | BBR       | 900 tid            |                        |              | 42   |                 |          |
| Zhang(a)* | 2017 | China  | MET       | 750 tid            | Yes                    | 55.2 (8.1)  | 33   | 3m              | FPG, 2hPBG, HbA1c |
|         |      |        | BBR       | 9000 tid           |                        | 54.9 (7.9)  | 33   |                 |          |
| Ye*     | 2021 | China  | MET       | 750 tid            | Unknown                | 65.23 (1.86) | 30   | 180d            | FPG, 2hPBG, HbA1c |
|         |      |        | BBR       | 9000 tid           |                        | 65.39 (1.36) | 30   |                 |          |
| Zhang(b)* | 2017 | China  | MET       | 750 + 9000 tid/tid | Yes                    | 58.24 (6.15) | 40   | 3m              | FPG, 2hPBG, HbA1c |
|         |      |        | BBR       | 750 + 9000 tid/tid |                        | 58.13 (6.24) | 40   |                 |          |
| Zhu      | 2015 | China  | GLC       | 30 qd              | Yes                    | 65.6 (7.2)  | 59   | 12w             | FPG, 2hPBG, HbA1c |
|         |      |        | GLC+BBR   | 30 + 300 qd/tid    |                        | 66.4 (7.6)  | 59   |                 |          |
| Li and Liu | 2007 | China  | GLP       | 15 qd              | Unknown                | 52 (14)      | 50   | 60d             | FPG, 2hPBG, HbA1c |
|         |      |        | BBR       | 15 + 900 qd/tid    |                        | 51           | 51   |                 |          |
| Yao      | 2015 | China  | GLP+MET   | 5 + 1500 qd/tid    | Yes                    | 43.2 (3.2)  | 38   | 3m              | FPG, 2hPBG, HbA1c |
|         |      |        | GLP+MET+BBR | 5 + 1500 + 1500 qd/ |                | 44.9 (2.8)  | 38   |                 |          |
| Sheng    | 2009 | China  | GLP+MET   | 10 + 1500 bid/tid  | Yes                    | 51.9 (10.7) | 30   | 3m              | FPG      |
|         |      |        | GLP+MET+BBR | 10 + 1500 + 1500 bid/ |            | 48.0 (10.2) | 30   |                 |          |
| Ye       | 2010 | China  | GLM+MET   | 200 + 1500 bid/tid | Unknown                | 42.5 (8.6)  | 40   | 3m              | FPG, 2hPBG, HbA1c |
|         |      |        | GLM+MET+BBR | 200 + 1500 bid/ |            | 43.5 (9.8)  | 40   |                 |          |
| Xu and Yu | 2008 | China  | PIO       | 30 qd              | Yes                    | 43.4 (2.1)  | 32   | 12w             | FPG, 2hPBG |
|         |      |        | PIO+BBR   | 30 + 900 qd/tid    |                        | 43.6 (2.1)  | 32   |                 |          |
| Wei      | 2021 | China  | MET+Ac    | 1000 + 150 bid/tid | Unknown                | 51.6 (7.2)  | 58   | 3m              | FPG, 2hPBG, HbA1c |
|         |      |        | MET+BBR+Ac | 1000 + 1500 bid/ |            | 50.8 (6.9)  | 58   |                 |          |
| Yang     | 2010 | China  | Ac        | 75–300 tid         | Yes                    | 53.9 (9.8)  | 25   | 3m              | FPG, 2hPBG, HbA1c |
|         |      |        | Ac+BBR    | (75–300) + 2400 tid/tid |                | 55.5 (9.1)  | 24   |                 |          |

**MET** metformin, **BBR** Berberine, **SUS** Sulfonylureas, **GLP** glipizide, **GLC** gliclazide, **GLM** glimepiride, **TZDs** thiazolidinediones, **PIO** pioglitazone, **Ac** acarbose.

* The Sulfonylureas originally taken were also used during the interventions, but the specific dose wasn’t mentioned.

1: The types and doses of OHAs are not mentioned.
2: The types of OHAs included PIO (10/25), GLM (10/25), GLC (5/25). The dose of OHAs was not mentioned.
incomplete outcome data or selective reporting was perceived as low risk nearly in all included studies, and risk of other bias was assessed as low mostly. The detailed quality assessments across the recruited studies were presented in Figure 2.

3.4 Main results of the meta-analysis

### 3.4.1 FPG

FPG was used to compare the efficacy of the experimental group with the control group in 37 studies (Liu, 2004; Cao, 2007; Li and Liu, 2007; You and Liu, 2007; Li, 2008; Liu and Hu, 2008;...)

| Study          | Baseline Mean FPG | Control | Experimental | Mean |
|---------------|-------------------|---------|--------------|------|
| Gu et al. (2010) | 6.9               | 6.9     | 6.9          |
| Zhang et al. (2008) | 6.8             | 7.0     | 6.9          |
| Yin (2011)     | 7.4               | 7.2     | 7.3          |
| Yao and Xie (2015) | 7.5             | 7.3     | 7.4          |
| Xu (2008)      | 7.4               | 7.4     | 7.4          |
| Wang (2008)    | 7.46              | 7.37    | 7.415        |

### 3.4.2 HbA1c

HbA1c, glycosylated hemoglobin.

| Study          | Baseline Mean HbA1c | Control | Experimental | Mean |
|---------------|---------------------|---------|--------------|------|
| Liu (2013)    | 8.7                 | 9.0     | 8.85         |
| Sun (2017)    | 8.75                | 8.96    | 8.855        |
| Zhe et al. (2020) | 9.03             | 9.01    | 9.02         |
| Dong et al. (2017) | 9.15            | 9.14    | 9.145        |
| Wei and Deng (2021) | 9.2              | 9.2     | 9.2          |
| Liu (2004)    | 9.4                 | 9.1     | 9.25         |
| Yang et al. (2020) | 9.2              | 9.3     | 9.25         |
| Li (2014)     | 9.31                | 9.32    | 9.315        |
| Lang and Zhu (2016) | 9.33            | 9.35    | 9.34         |
| Fan et al. (2018) | 9.59             | 9.60    | 9.595        |
| Jiang and Wang (2019) | 10.01           | 9.79    | 9.9          |
| Zhang and Yuan (2012) | 10.01           | 9.82    | 9.915        |
| Zhe et al. (2015) | 10.23            | 9.93    | 10.08        |
| Rashidi et al. (2018) | 9.93            | 10.67   | 10.3         |
| Yang (2010)   | 10.5                | 10.7    | 10.6         |
| Li (2008)     | 10.7                | 10.6    | 10.65        |
| Zhang (2017)  | 10.9                | 11.0    | 10.95        |
| Li and Liu (2007) | 11.2             | 11.1    | 11.15        |
| Li (2016)     | 11.1                | 11.2    | 11.15        |
| Xue et al. (2012) | 11.0             | 11.3    | 11.15        |
| Ye (2021)     | 10.75               | 11.97   | 11.36        |
| Zhang and Chen (2017) | 11.4             | 11.5    | 11.45        |
| Zhe et al. (2009) | 13.3              | 13.3    | 13.3         |

FPG, fasting plasma glucose.
Wang, 2008; Xu, 2008; Yang, 2008; Zhang et al., 2008; Sheng, 2009; Zhu et al., 2009; Gu et al., 2010; Yang, 2010; Ye, 2010; Xiang et al., 2011; Yin, 2011; Xue et al., 2012; Zhang and Yuan, 2012; Liu, 2013; Li, 2014; Yao and Xie, 2015; Zhu et al., 2015; Lang and Zhu, 2016; Li, 2016; Dong et al., 2017; Sun, 2017; Zhang, 2017; Zhang and Chen, 2017; Fan et al., 2018; Rashidi et al., 2018; Jiang and Wang, 2019; Yang et al., 2020; Yu, 2020; Zhu et al., 2020; Wei and Deng, 2021; Ye, 2021) involving 3,048 patients. The meta-analysis showed that, after treatment, FPG in the experimental group was lower than that in the control group (random effects model, WMD = -0.82 mmol/L, 95% CI (-0.95, -0.70), p < 0.001). This result was statistically significant. However, there was significant heterogeneity (I^2 = 60% > 50%, p < 0.001). Therefore, we performed a subgroup analysis according to baseline mean FPG.

As demonstrated by the result of subgroup analysis in Table 5 and Figure 3, FPG in the experimental group was lower than that in the control group after treatment in each subgroup. The result was statistically significant (p < 0.001) without significant heterogeneity (I^2 < 50%).

Sensitivity analyses were conducted to assess changes in FPG by excluding the report of apparently poor quality (Liu, 2013) and eliminating studies with too short treatment duration (≤3w) (Liu, 2004; You and Liu, 2007). The results of meta-analysis were not substantially changed (Excluding the report of apparently poor quality: WMD = -0.82 mmol/L, 95% CI (-0.96, -0.69), p < 0.001, I^2 = 61%; Eliminating studies with too short treatment duration: WMD = -0.83 mmol/L, 95% CI (-0.96, -0.70), p < 0.001, I^2 = 61%) (Figures 4A,B). Egger’s test showed that there was no obvious publication bias (p = 0.079 > 0.05) and the funnel plots for FPG was largely symmetric (Figure 5).

3.4.2 HbA1c

HbA1c was used to compare the efficacy of the experimental group with the control group in 31 studies (Cao, 2007; Li and Liu, 2007; Liu and Hu, 2008; Wang, 2008; Yang, 2008; Zhang et al., 2008; Zhu et al., 2009; Gu et al., 2010; Yang, 2010; Ye, 2010; Xiang et al., 2011; Yin, 2011; Xue et al., 2012; Zhang and Yuan, 2012; Dong et al., 2017; Sun, 2017; Zhang, 2017; Zhang and Chen, 2017; Fan et al., 2018; Jiang and Wang, 2019; Yang et al., 2020; Yu, 2020; Zhu et al., 2020; Wei and Deng, 2021; Ye, 2021) involving 2,683 patients. The meta-analysis showed that, after treatment, HbA1c in the experimental group was lower than that in the control group (random effects model, WMD = -0.63%, 95% CI (-0.72, -0.53), p < 0.001). This result was statistically significant. However, there was significant heterogeneity (I^2 = 52% > 50%, p < 0.001). Therefore, we performed subgroup analyses according to baseline mean HbA1c and FPG. The result of subgroup analysis is presented in Table 5 and Figure 6. When subgroup analysis was performed according to baseline mean HbA1c after treatment, in each subgroup, HbA1c in the experimental group was lower than that in the control group. The result was statistically significant (p < 0.001) without significant heterogeneity (I^2 < 50%).
When subgroup analysis was performed according to baseline mean FPG, after treatment, HbA1c in the experimental group was lower than that in the control group and the result was statistically significant ($p < 0.05$) in each subgroup. When baseline mean FPG was <7.5 mmol/L or ≥10.0 mmol/L, there was no significant heterogeneity ($I^2 < 50\%$, $p > 0.1$). However, when baseline mean FPG was ≥7.5 and <10.0 mmol/L, there was significant heterogeneity ($I^2 > 50\%$) (Figure 6B).

Egger's test showed that there was no obvious publication bias ($p = 0.812 > 0.05$).

### 3.4.3 2hPBG

2hPBG was used to compare the efficacy of the experimental group with the control group in 34 studies (Liu, 2004; Cao, 2007; Li and Liu, 2007; Li, 2008; Liu and Hu, 2008; Wang, 2008; Xu, 2008; Yang, 2008; Zhang et al., 2008; Zhu et al., 2009; Gu et al., 2010; Yang, 2010; Ye, 2010; Xiang et al., 2011; Yin, 2011; Xue et al., 2012; Zhang and Yuan, 2012; Liu, 2013; Li, 2014; Yao and Xie, 2015; Zhu et al., 2015; Lang and Zhu, 2016; Li, 2016; Dong et al., 2017; Sun, 2017; Zhang, 2017; Zhang and Chen, 2017; Fan et al., 2018; Rashidi et al., 2018; Jiang and Wang, 2019; Yang et al., 2020; Yu, 2020; Wei and Deng, 2021; Ye, 2021) involving 2,884 patients. The meta-analysis showed that, after treatment, 2hPBG in the experimental group was lower than that in the control group (random effects model, WMD = -1.16 mmol/L, 95% CI (-1.36, -0.96), $p < 0.001$). This result was statistically significant. Meanwhile, there was also significant heterogeneity ($I^2 = 68\% > 50\%$, $p < 0.001$). Therefore, we performed subgroup analyses according to the baseline mean HbA1c and FPG. The result of the subgroup analysis is presented in Table 5 and Figure 7. No matter how subgroups were divided, after treatment, in each subgroup, HbA1c in the experimental group was always lower than that in the control group and the result was statistically significant ($p < 0.001$).

### Table 5 The results of subgroup analyses.

| Subgroups | n  | WMD  | 95% CI          | p-value | Heterogeneity between studies |
|-----------|----|------|----------------|---------|-------------------------------|
| FPG (mmol/L) |    |      |                |         |                               |
| Overall   | 37 | -0.82| (-0.95, -0.70) | <0.001  | $I^2 = 60\% p < 0.001$       |
| Baseline mean FPG |    |      |                |         |                               |
| <7.5 mmol/L | 6  | -1.02| (-1.15, -0.89) | <0.001  | $I^2 = 0\% p = 0.45$         |
| 7.5 mmol/L ~ 8.8 mmol/L | 7  | -0.55| (-0.82, -0.29) | <0.001  | $I^2 = 56\% p = 0.15$        |
| 8.8 mmol/L ~ 10.0 mmol/L | 13 | -1.07| (-1.23, -0.91) | <0.001  | $I^2 = 48\% p = 0.03$        |
| ≥10.0 mmol/L | 11 | -0.51| (-0.70, -0.32) | <0.001  | $I^2 = 4\% p = 0.40$         |
| HbA1c (%) |    |      |                |         |                               |
| Overall   | 31 | -0.63| (-0.72, -0.53) | <0.001  | $I^2 = 52\% p < 0.001$       |
| Baseline mean HbA1c |    |      |                |         |                               |
| <9.0%     | 21 | -0.58| (-0.69, -0.46) | <0.001  | $I^2 = 49\% p = 0.006$       |
| ≥9.0%     | 10 | -0.79| (-0.90, -0.67) | <0.001  | $I^2 = 6\% p = 0.38$         |
| Baseline mean FPG |    |      |                |         |                               |
| <7.5 mmol/L | 5  | -0.60| (-0.71, -0.49) | <0.001  | $I^2 = 0\% p = 0.92$         |
| 7.5 mmol/L ~ 8.8 mmol/L | 5  | -0.57| (-0.98, -0.17) | 0.006   | $I^2 = 62\% p = 0.03$        |
| 8.8 mmol/L ~ 10.0 mmol/L | 12 | -0.72| (-0.87, -0.57) | <0.001  | $I^2 = 62\% p = 0.002$       |
| ≥10.0 mmol/L | 9  | -0.51| (-0.70, -0.33) | <0.001  | $I^2 = 4\% p = 0.41$         |
| 2hPBG (mmol/L) |    |      |                |         |                               |
| Overall   | 34 | -1.16| (-1.36, -0.96) | <0.001  | $I^2 = 68\% p < 0.001$       |
| Baseline mean HbA1c |    |      |                |         |                               |
| <9.0%     | 21 | -1.38| (-1.69, -1.08) | <0.001  | $I^2 = 71\% p < 0.001$       |
| ≥9.0%     | 9  | -0.93| (-1.21, -0.64) | <0.001  | $I^2 = 50\% p = 0.04$        |
| Lacking data of baseline mean HbA1c | 4  | -0.78| (-0.93, -0.63) | <0.001  | $I^2 = 0\% p = 0.72$         |
| Baseline mean FPG |    |      |                |         |                               |
| <7.5 mmol/L | 6  | -1.35| (-1.97, -0.73) | <0.001  | $I^2 = 72\% p = 0.003$       |
| 7.5 mmol/L ~ 8.8 mmol/L | 5  | -1.21| (-1.85, -0.58) | <0.001  | $I^2 = 61\% p = 0.04$        |
| 8.8 mmol/L ~ 10.0 mmol/L | 12 | -1.19| (-1.58, -0.79) | <0.001  | $I^2 = 83\% p < 0.001$       |
| ≥10.0 mmol/L | 11 | -1.10| (-1.34, -0.86) | <0.001  | $I^2 = 0\% p = 0.85$         |

CI, confidence interval; WMD, weighted mean differences; HbA1c, glycylated hemoglobin; FPG, fasting plasma glucose; 2hPBG, 2-h postprandial blood glucose.
### FIGURE 3
Meta-analysis of the effect of BBR on FPG.

| Study or Subgroup | Mean FPG (mmol/L) | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|-------------------|-------------------|-----------------------------------|-----------------------------------|
| **Baseline FPG < 7.5 mmol/L** |                  |                                   |                                   |
| Gu and Zhang 2010 | 5.5 0.9 30 6.3 1.3 30 2.6% -0.80 [-1.37, -0.23] |                                   |                                   |
| Wang 2008         | 6.13 0.85 31 6.91 1.86 30 1.9% -0.78 [-1.54, -0.05] |                                   |                                   |
| Xu and Yu 2008    | 5.1 0.3 32 6.2 0.3 32 2.5% -1.10 [-1.25, -0.95] |                                   |                                   |
| Yuan 2015         | 5.9 1.2 38 6.6 0.9 38 3.1% -0.70 [-1.18, -0.22] |                                   |                                   |
| Yin 2011          | 5.8 1.7 30 6.7 1 30 2.0% -0.90 [-1.61, -0.19] |                                   |                                   |
| Zhang and Li 2008 | 5.6 0.9 37 6.4 1.6 49 2.9% -0.80 [-1.31, -0.29] |                                   |                                   |
| **Subtotal (95% CI)** | 218               |                                   |                                   |
| **Heterogeneity:** Tau^2=0.00, Chi^2=4.20, df=5 (P=0.45), I^2=0% |                                   |                                   |
| **Test for overall effect:** Z=15.70 (P=0.00001) |                                   |                                   |

| **Baseline FPG < 7.5 mmol/L** |                  |                                   |                                   |
| **Baseline FPG < 8.8 mmol/L** |                  |                                   |                                   |
| **Baseline FPG < 10.0 mmol/L** |                  |                                   |                                   |
| **Baseline FPG ≥ 10.0 mmol/L** |                  |                                   |                                   |

**Heterogeneity:** Tau^2=0.04, Chi^2=9.41, df=6 (P=0.15), I^2=36%

**Test for overall effect:** Z=4.07 (P=0.00001)

**Heterogeneity:** Tau^2=0.04, Chi^2=23.24, df=12 (P=0.15), I^2=48%

**Test for overall effect:** Z=12.93 (P=0.00001)

**Heterogeneity:** Tau^2=0.00, Chi^2=10.42, df=10 (P=0.40), I^2=4%

**Test for overall effect:** Z=5.29 (P=0.00001)

**Total (95% CI)** 1544 1534 100.0% -0.82 [-0.95, -0.70]

**Heterogeneity:** Tau^2=0.07, Chi^2=89.40, df=36 (P=0.00001), I^2=60%

**Test for overall effect:** Z=12.91 (P=0.00001)

**Test for subgroup difference:** Chi^2=29.94, df=3 (P=0.00001), I^2=90.0%

---

Favours [experimental] | Favours [control]
---|---
-2 | -1 | 0 | 1 | 2

---

Frontiers in Pharmacology 11 frontiersin.org
FIGURE 4
Sensitivity analyses by exclusion of apparently poor quality reports and exclusion of studies with too short treatment duration (≤3w). (A) Sensitivity analysis by exclusion of apparently poor quality reports (B) Sensitivity analysis by exclusion of studies with too short treatment duration (≤3w).

FIGURE 5
Funnel plot for FPG.
significant heterogeneity ($I^2 < 50\%$, $p > 0.1$) only if baseline mean HbA1c was $\geq 9\%$ or baseline mean FPG was $\geq 10.0$ mmol/L (Figures 7A,B).

Egger’s test showed that there was obvious publication bias ($p = 0.006 < 0.05$).

### 3.4.4 Safety of berberine on patients with T2DM

The incidence of total adverse events was used to assess the safety of berberine in 14 studies (Liu, 2004; Zhang et al., 2008; Zhu et al., 2009; Yang, 2010; Yin, 2011; Zhang and Yuan, 2012; Liu, 2013; Yao and Xie, 2015; Zhu et al., 2015; Sun, 2017; Rashidi et al., 2018; Jiang and Wang, 2019; Yu, 2020; Wei and Deng, 2021), including a total of 670 patients in the experimental group and 651 in the control group. Data revealed that berberine alone or in combination with OHAs in the treatment of T2DM had a lower incidence of total adverse events and appeared to have better safety compared to the control group (fixed effects model, $RR = 0.73$, 95% CI $(0.55, 0.97)$, $p = 0.03$). The result was of statistically significance without significant heterogeneity ($I^2 < 50\%$, $p > 0.1$) (Figure 8A). Egger’s test showed that there was no obvious publication bias ($p = 0.234 > 0.05$).

Hypoglycemia was used to further compare the safety of the experimental group to the control group in nine studies (Li, 2008; Xu, 2008; Zhang et al., 2008; Sheng, 2009; Zhu et al., 2009; Liu, 2013; Yao and Xie, 2015; Yu, 2020) involving 820 patients. In seven (Li, 2008; Xu, 2008; Zhang et al., 2008; Sheng, 2009; Zhu et al., 2009; Yao and Xie, 2015; Yu, 2020) of the nine studies, there were no hypoglycemic episodes in either the experimental group or the control group, and the remaining two studies (Liu, 2013; Zhu et al., 2015) reported hypoglycemia. Meta-analysis of those two studies, including 186 patients, showed that there were no significant differences in hypoglycemia between the experimental and control groups (fixed effects model, $RR = 0.48$, 95% CI $(0.21, 1.08)$, $p = 0.08$). There was no significant heterogeneity ($I^2 = 23\% < 50\%$, $p > 0.1$) (Figure 8B).

### 3.4.5 Certainty of evidences

The certainty of evidences of FPG, HbA1c and total adverse events was all moderate, because it was downgraded of a level for risk of bias. The certainty of evidence of 2hPBG was low because of risk of bias and publication bias. The certainty of evidence of hypoglycemia was very low because of risk of bias and imprecision (Table 6).

### 4 Discussion

This meta-analysis showed that BBR was effective in the treatment of T2DM and reduced FPG, HbA1c, and 2hPBG in patients with T2DM. In subgroup analyses according to the baseline mean FPG and HbA1c, the reduction of FPG, HbA1c, and and Xie, 2015; Yu, 2020) of the nine studies, there were no hypoglycemic episodes in either the experimental group or the control group, and the remaining two studies (Liu, 2013; Zhu et al., 2015) reported hypoglycemia. Meta-analysis of those two studies, including 186 patients, showed that there were no significant differences in hypoglycemia between the experimental and control groups (fixed effects model, $RR = 0.48$, 95% CI $(0.21, 1.08)$, $p = 0.08$). There was no significant heterogeneity ($I^2 = 23\% < 50\%$, $p > 0.1$) (Figure 8B).

3.4.5 Certainty of evidences

The certainty of evidences of FPG, HbA1c and total adverse events was all moderate, because it was downgraded of a level for risk of bias. The certainty of evidence of 2hPBG was low because of risk of bias and publication bias. The certainty of evidence of hypoglycemia was very low because of risk of bias and imprecision (Table 6).

### 4 Discussion

This meta-analysis showed that BBR was effective in the treatment of T2DM and reduced FPG, HbA1c, and 2hPBG in patients with T2DM. In subgroup analyses according to the baseline mean FPG and HbA1c, the reduction of FPG, HbA1c,
or 2hPBG in each subgroup was statistically significant. Furthermore, we found that the baseline mean FPG was the source of heterogeneity of studies with FPG and both baseline mean FPG and HbA1c were sources of heterogeneity for HbA1c and 2hPBG, suggesting that the glucose-lowering effects of BBR correlated with baseline mean FPG and HbA1c. When baseline mean FPG was ≥10 mmol/L, I² values of heterogeneity tests for studies focusing on FPG, HbA1c and 2hPBG were all less than 50%, indicating very small heterogeneity. So, the reduction effect of BBR on FPG, HbA1c, and 2hPBG was reliable in this subgroup. When baseline mean FPG was <7.5 mmol/L, I² values of heterogeneity tests for studies focusing on FPG and HbA1c were both 0%, indicating that there is no significant heterogeneity. Therefore, the reduction effect of BBR on FPG and HbA1c was also reliable in this subgroup. Regarding safety, our findings suggested that berberine alone or in combination with OHAs in the treatment of T2DM did not increase the incidence of total adverse events and the risk of hypoglycemia. Berberine may even have the potential advantage of reducing the risk of adverse reactions when used as adjuvant therapy, but further studies are still needed to verify it. Therefore, berberine is a viable treatment option for T2DM. After rating with GRADE approach, the certainty of evidences of FPG, HbA1c and total adverse events was all moderate. It was low for 2hPBG and very low for hypoglycemia.

4.1 Comparison with previous meta-analysis

So far, there have been four meta-analyses on the therapeutic effects of BBR on T2DM. They have confirmed that BBR can improve blood glucose level, lipid metabolism, and inflammatory markers in diabetic patients, as well as treating hyperlipidemia and hypertension (Dong et al., 2012; Lan et al., 2015; Liang et al., 2019; Guo et al., 2021). The two latest meta-analyses also found that the effect of BBR in the treatment of diabetes was related to daily dosage, age, and treatment duration. But there was obvious heterogeneity among the included studies, especially in those focused on FPG. After subgroup analysis, the problem of heterogeneity still existed (Liang et al., 2019; Guo et al., 2021). Large heterogeneity reduced the reliability of the two meta-analyses. According to our meta-analysis, we found that one of the sources of heterogeneity of FPG was the baseline mean FPG, and sources of heterogeneity of HbA1c and 2hPBG included baseline mean FPG and HbA1c. In particular, for FPG, subgroup analysis based on baseline FPG reduced the heterogeneity of each subgroup to I² < 50%. The reduction of heterogeneity made the conclusion of our meta-analysis more reliable.
4.2 Significant advantages and broad application prospects of BBR

Compared with existing glucose-lowering agents, berberine has significant advantages and broad application prospects, which are briefly reviewed as follows: 1) Berberine has multiple glucose-lowering mechanisms, including improving insulin resistance, regulating glucose metabolism, regulating blood lipid metabolism, anti-inflammatory effects, protecting islet cells, and antioxidant effects (Li et al., 2021). In addition, the latest research by Professor Yang Jinkui’s team in 2021 found that by inhibiting the KCN6 potassium channel, berberine has a brand-new glucose-dependent insulinotropic effect and can treat diabetes while avoiding the risk of hypoglycemia (Zhao et al., 2021); 2) Berberine can relieve and prevent a variety of diabetic complications, including diabetic encephalopathy, diabetic nephropathy, diabetic cardiomyopathy, and has a protective effect on the nerves of diabetic peripheral neuropathy (Li et al., 2021); 3) One drug is commonly used for multiple purposes with a wide range of clinical values: berberine has multiple pharmacological effects, including anti-hyperglycemia, anti-hyperlipidemia, anti-hypertension, cardiovascular protection, anti-arrhythmia, improvement of congestive heart failure, anti-bacterial, fungal, viral and other pathogenic microorganisms, anti-inflammatory, antioxidant, anti-tumor and anti-platelet aggregation. Some pharmacodynamic effects of berberine have been reported in clinical application, but some pharmacological effects, including anti-tumor, are still limited to laboratory and studies (Li et al., 2008; Xing et al., 2017; Zhou et al., 2020); 4) Based on intestinal flora regulation, protection of the barrier of the intestinal mucosa and broad-spectrum antibacterial effects (Hou et al., 2022), berberine can treat diarrhea caused by a variety of bacteria, reduce the number of diarrhea (Lang and Zhu, 2016), while improving blood glucose abnormalities caused by intestinal microbial disorders (Zhu et al., 2020); 5) Berberine can inhibit genes for fat synthesis, inhibit the differentiation of preadipocytes into mature adipocytes, and reduce lipid accumulation, indicating that berberine can slightly reduce body weight (Li et al., 2008). In addition, berberine has been found to significantly reduce leptin levels in patients with type 2 diabetes (Wang, 2008), all of which suggest that berberine is suitable for the treatment of obese patients with type 2 diabetes; 6) Berberine, as a natural isoquinoline alkaloid extracted from Coptis chinensis and other plants, has the characteristics of low toxicity, fewer side effects, and good tolerability. Berberine has long been proved to be a drug without cytotoxic and mutagenic effects and with a very high safety factor through biochemical, pharmacological, and clinical studies. Reliable data suggests that berberine has fewer side effects than western medicine and no toxic effects on blood urea nitrogen and serum creatinine in most laboratory and clinical trials (Yang et al., 2020) (Chang et al., 2015; Liang et al., 2019) Only a small proportion of patients treated with berberine experience reflux, vomiting, diarrhea, or constipation; 7) Some marketed glucose-lowering agents are limited in their use due to their high price relative to the inexpensive berberine. Chinese medicinal materials are rich in resources, coptis chinensis is abundant, berberine is
### TABLE 6 Summary of findings table.

| Certainty assessment | No of patients | Effect | Certainty | Importance |
|----------------------|----------------|--------|------------|------------|
|                      | BBR+placebo/OHAs | placebo/OHAs | Relative (95% CI) | Absolute (95% CI) |
| FPG                  | 1544           | 1504   | -          | MD 0.82 mmol/L lower (0.95 lower to 0.7 lower) |
|                      |                |        |            | Moderate   | IMPORTANT |
| HbA1c                | 1352           | 1331   | -          | MD 0.63 % lower (0.72 lower to 0.53 lower) |
|                      |                |        |            | Moderate   | IMPORTANT |
| 2hPBG                | 1454           | 1430   | -          | MD 1.16 mmol/L lower (1.36 lower to 0.96 lower) |
|                      |                |        |            | Low        | IMPORTANT |
| Total adverse events| 66/670 (9.9%)  | 89/651 (13.7%) | RR 0.73 (0.55 to 0.97) | 37 fewer per 1,000 (from 62 fewer to 4 fewer) |
|                      |                |        |            | Moderate   | IMPORTANT |
| Hypoglycemia         | 7/95 (7.4%)    | 15/91 (16.5%) | RR 0.48 (0.21 to 1.08) | 86 fewer per 1,000 (from 130 fewer to 13 more) |
|                      |                |        |            | Very low   | IMPORTANT |

CI confidence interval, MD mean difference, RR risk ratio.

* Most information is from studies at low or unclear risk of bias. Potential limitations are likely to lower confidence in the estimate of effect.

* Egger’s test showed that there was obvious publication bias.

* The optimal information size criterion is not met. The 95% CI overlaps no effect and fails to exclude important benefit.
extracted from coptis chinensis, and the current drug production process has been artificially synthesized, so berberine is widely available and low-cost. In addition, berberine has fewer adverse reactions, easy to be accepted and adhered to by patients, and can also be used during pregnancy or delivery, which is worthy of clinical promotion (Liao and Hao, 2020).

Berberine can compensate for the weaknesses of existing glucose-lowering agents and play a good auxiliary role in the treatment of type 2 diabetes. Sulfonylurea hypoglycemic agents such as glipizide are mainly effective in patients with certain insulin synthesis and secretion function in islet β cells, and long-term use of sulfonylureas can cause a decrease in the number and affinity of sulfonylurea receptors on islet G cells, which disables the drug and also has the risk of leading to severe hypoglycemia. However, recent studies have shown that berberine can promote the regeneration of islet β cells to a certain extent and restore islet function. In addition, according to research findings, the blood glucose value of berberine combined with glipizide is more stably controlled than that of glipizide alone, indicating that berberine and glipizide have a good synergistic effect (Li and Liu, 2007). Diarrhea and other gastrointestinal symptoms are common when metformin is used in the early stage, and it is contraindicated in patients with severe liver and kidney dysfunction. Metformin still has certain limitations as a first-line drug for the treatment of diabetes (Liao and Hao, 2020). Berberine has no hepatorenal side effects, and like metformin, it can enhance the sensitivity of insulin receptors in peripheral tissues of patients, thereby lowering blood glucose, which has a good synergistic effect (Zhu et al., 2009). Berberine can reduce the intestinal absorption of glucose and reduce postprandial hyperglycemia, as a new α-glycophorin inhibitor, berberine itself has a certain bactericidal and bacteriostatic effect, which can avoid the side effects such as abdominal pain and diarrhea caused by the fermentation of intestinal (mainly colon) flora due to the inhibition of carbohydrate absorption (Li et al., 2008). Exogenous insulin must be used by injection, which is extremely inconvenient, and excessive use will also aggravate obesity and insulin resistance, thereby increasing the incidence of complications such as coronary heart disease and hypertension. And exogenous insulin also has the potential risk of causing hypoglycemia (Lang and Zhu, 2016; Li et al., 2021). In comparison, berberine can increase insulin sensitivity, reduce insulin dosage, while helping to reduce fat and control body weight (Li et al., 2008). To sum up, berberine is a highly effective and low-risk alternative and synergistic treatment regimen, which has significant advantages and broad application prospects.

4.3 Glucose-lowering effects of BBR and recommendations for future studies

10.7% of emergency hospitalizations in adults 65 and older were due to OHAs. Hypoglycemia accounted for 94.6% of emergency hospitalizations for endocrine drugs (Budnitz et al., 2011). It occurs in T2DM patients, when measurable glucose concentration is less than 3.9 mmol/L (Dräzin et al., 2022). In clinical practice, treatment of T2DM should minimize the risk of hypoglycemia. In OHAs, sulfonylureas and glinides can close the KATP channel, depolarize the pancreatic β-cell membrane and lead to calcium influx and insulin release (Lv et al., 2020). Among the adverse events caused by sulfonylureas, hypoglycemia is the most common one. In addition, glinides also having side effects of hypoglycemia (Klein-Schwartz et al., 2016; Garber et al., 2020; Lv et al., 2020). As an insulin secretory agent, BBR has glucose-lowering effects that is dependent on hyperglycemia, meaning that it may not lead to hypoglycemia (Zhao et al., 2021). In the two meta-analyses from 2019 to 2021 (Li et al., 2019; Guo et al., 2021), the reviewers compared the glucose-lowering efficacy of BBR and the OHAs commonly used in clinical practice in the subgroup analysis, and there was no significant difference in the effect of the two kinds of drugs on FPG, HbA1c, and 2hPBG. This indicates that the glucose-lowering effects of BBR is similar to that of existing OHAs, and may have the advantage of not causing hypoglycemia.

Among the ion channels associated with glucose-stimulated insulin secretion (GSIS) from pancreatic islet β cells, the three most important ones are KATP channels, voltage-gated k+(kV) channels and voltage-gated Ca2+channels (VGCC) (Yang et al., 2014). In addition, voltage-gated sodium channels (VGSC) and transient receptor potential melastatin 2 (TRPM2) by acetylcholine also play important roles in insulin secretion (Rolland et al., 2002; Yang et al., 2014; Kakei et al., 2016). When blood glucose concentration increases, glucose is taken up into the pancreatic β cells through glucose transporters (GLUT) and converted to ATP during aerobic oxidation. If the ATP/adenosine diphosphate (ADP) ratio rises to a sufficiently high level, KATP channels will be closed, resulting in the inhibition of potassium outflow and the slow depolarization of pancreatic islet β-cell membrane. The membrane potential, which reaches the threshold of action potentials, activates VGCC to let the extracellular Ca2+ flow in. The increase of intracellular Ca2+ promotes insulin secretion. Thereafter, K+ channels will be activated to repolarize cell membrane. Then, the repolarization will close VGCC and stop Ca2+ influx and insulin secretion (Yang et al., 2014; Sun H. Z. et al., 2022).

There are many K+ channels expressed in human islets, such as Kv1.6, Kv2.1, Kv3.2, Kv11.1, Kv11.2 and so on (Finol-Urdeneta et al., 2012; Jacobson and Shyng, 2020). The gene, KCNH6, encodes the Kv11.2 channel, which is the target of BBR (Jacobson and Shyng, 2020; Zhao et al., 2021). BBR binds to KCNH6 potassium channel, making it close faster, and then inhibits the repolarization of pancreatic islets β-cell membrane. This will prolong the duration of cell membrane action potential and allow more Ca2+ to enter the cell through VGCC, so as to increase the secretion of insulin (Zhao et al., 2021). The repolarization of pancreatic islets β-cell membrane is
secondary to glucose-mediated $K_{ATP}$ closure and depolarization of pancreatic islet β-cell membrane. If glucose level is low and glucose-mediated $K_{ATP}$ channel closure does not occur, inhibition of the KCNHex potassium channel by BBR will not cause insulin secretion. That is to say, the effect of BBR in promoting insulin secretion is hyperglycemic dependent. So, BBR does not affect fasting insulin and blood glucose levels. In Zhao’s hyperglycemic clamp experiment involving 15 healthy men, BBR did not change subjects’ fasting blood glucose, fasting insulin, and fasting C-peptide compared with placebo (Zhao et al., 2021). As another Kv channel similar to KCNHex, Kv1.7 channel has been experimentally studied for its role in promoting insulin secretion. In a study, the researchers used Conkunitzin-S1 to selectively inhibit Kv1.7 channels in rat pancreatic islets. It was found that Conkunitzin-S1 increased insulin secretion at 10 and 16 mM glucose concentrations compared to 0 mM glucose concentrations (Finol-Urdaneta et al., 2012).

According to our meta-analysis, BBR has glucose-lowering effects, which is related to baseline FPG and HbA1c. However, how baseline glucose levels affect the therapeutic effect of BBR on diabetes and what is the specific mechanism still remains unclear. In addition, previous studies have found that glyburide, as an inhibitor of $K_{ATP}$ channel, differentially promoted insulin secretion in different blood glucose concentrations (Ligtenberg et al., 1997; Riefflin et al., 2015). As an inhibitor of Kv channel, the role of BBR in promoting insulin secretion in different blood glucose concentrations remains unclear. Subsequent studies should explore the different insulin-stimulating effects of BBR in different levels of blood glucose concentrations, such as low, moderately elevated, and high levels, and the different therapeutic effects of BBR on FPG, HbA1c, 2hPBG and other indicators reflecting diabetes in different baseline glucose levels.

When stimulated by glucose, insulin is secreted from pancreatic islet β cells in two phases. In the first phase, insulin secretion reaches a rapid peak and then declines. Then it will enter the second phase and gradually increase again (Ligtenberg et al., 1997). Early insulin secretion usually refers to the insulin secretion between 0 and 30min, including the first phase and part of the second phase. It is very important to control postprandial blood glucose (Pratley and Weyer, 2001). It is well known that sulfonylureas and glinides are the most commonly used insulin secretory agents in clinical practice. As a mealtime blood glucose regulator, the main function of glinides is to promote early insulin secretion. Sulfonylureas act slowly, so they are often not used as dietary glucose regulators. In a study (Zhao et al., 2021), BBR promoted insulin secretion in the first phase, but the result was not statistically significant. BBR also promoted insulin secretion in the second phase and overall total secretion. This result was statistically significant. In our meta-analysis, BBR reduced both FPG and 2hPBG. Therefore, BBR may be an insulin secretory agent that mainly reduces FPG but also has the effect of reducing PBG. More studies are needed to verify this hypothesis.

There was a question that our study has not been able to resolve. Firstly, Yang’s study found that, on insulin secretion, the effect of BBR depends on high blood glucose concentration. BBR had no significant effect on fasting blood glucose, fasting insulin, or fasting C-peptide levels. It is worth noting that the subjects in this trial were healthy men with normal glucose tolerance (Zhao et al., 2021). What is the effect of BBR when used in diabetic patients? In our meta-analysis, the results showed that BBR can reduce FPG in patients with T2DM. The difference between the results of our meta-analysis and those of Yang’s study may be due to the different baseline blood glucose levels of the included patients. So when will the glucose-lowering effects of BBR stop in the process of blood glucose reduction? (Di Pierro et al., 2012).

In addition to BBR, previous studies have found a variety of other herb extracts which target ion channels in the cell membrane of pancreatic islet β cells. Baicalein, a kind of flavonoid extracted from scutellaria baicalensis, can inhibit Kv channel (Guo et al., 2018). Vindoline, the alkaloids of Catharanthus roseus, can inhibit Kv2.1 channel (Yao et al., 2013). Both baicalein and vindoline can prolong the duration of cell membrane action potential and increase the secretion of insulin. Geniposide, an iridoid glycoside extracted from the fruit of Gardenia jasminoides Ellis, can inhibit Kv channel and activate VGCC, so as to make more Ca$^{2+}$ enter the cell and increase the secretion of insulin (Zhang et al., 2016). Geniposidic acid is also one of the components of the total glycosides of Plantaginis Semen (Tong, 2019). All of these compounds—BBR, baicalein, vindoline and geniposide—are Kv channel inhibitors. When blood glucose concentration rises, $K_{ATP}$ channels close and action potentials are generated, therefore Kv channel inhibitors increase insulin secretion by inhibiting Kv channels and increasing calcium influx. In other words, the glucose-lowering effects of Kv channel inhibitors is secondary to the increase of blood glucose concentration. Therefore, Kv channel inhibitors do not affect fasting insulin or glucose levels (Zhao et al., 2021; Sun H. Z. et al., 2022).

It is worth noting that, as the sources of BBR, baicalein and geniposide, rhizoma coptidis, scutellaria baicalensis, phellodendri chinensis and gardenia jasminoides are main herbs of Huanglian Jiedu Decoction, which have been used to treat diabetes in China for more than a thousand years (Wu et al., 2019). By further studying the mechanisms for lowering blood glucose of herbal extracts that can inhibit Kv channel, such as BBR, baicalein, vindoline, and geniposide, new insulin secretagogues may be developed that do not cause hypoglycemia.
5 Strengths and limitations

Compared with previous meta-analyses, our study is the first to conduct a subgroup analysis according to patients' baseline mean FPG and HbA1c levels to investigate the source of heterogeneity. In a meta-analysis (Liang et al., 2019), through subgroup analyses, reviewers found that the intervention, patient age, daily dose of BBR, and duration of treatment led to significant heterogeneity. Our study identified that the glucose-lowering effects of BBR were also correlated with baseline mean FPG and HbA1c, which represented the patient’s blood glucose levels before the BBR intervention. Furthermore, our study resolved the problem of large heterogeneity existing in previous meta-analyses to some extent through subgroup analysis, and provided more reliable evidence for the glucose-lowering effects of BBR.

However, this review also has limitations. First, the included studies of 2hPBG had publication bias. This may affect the credibility of the meta-analysis results on 2hPBG. Secondly, the included studies were mostly conducted in China, lacking adequate global data, which weakens the extrapolation of the results. What’s more, the duration of treatment is short in some studies, which is not conducive to fully evaluating the safety of berberine in the treatment of T2DM. Additionally, the quality of the articles was uneven. Some trials did not use blinding or allocation concealment methods, which may lead to information bias due to the influence of subjective factors. But when we performed sensitivity analyses by eliminating studies with too short treatment duration (≤3w) and excluding the article of apparently poor quality from the analysis of FPG, the results of meta-analysis were not substantially changed, which suggests our findings were stable.

There are few high-quality large-scale clinical trials using BBR in the treatment of T2DM. It is suggested that relevant clinical trials in the future should follow the relevant principles of randomization, allocation concealment, and double blinding, and be described in detail in the methodology section. Large sample, multicenter, and high-quality clinical studies are needed to confirm the benefit of BBR in T2DM.

6 Conclusion

Our systematic review and meta-analysis showed that BBR has a glucose-lowering effect, which is related to baseline FPG and HbA1c levels of patients. The addition of BBR to lifestyle modifications or existing OHAs does not increase the incidence of total adverse events and the risk of hypoglycemia. Studies on BBR are expected to develop new glucose-lowering agents in the future.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Author contributions

The conception and topic selection of the manuscript were carried out by WX, FS and GW. The protocol registered on PROSPERO was completed by ZP. Literature retrieval and screening were completed by WX and YX. ZP and WX conducted data extraction and statistics and table making. WX, FS and GW completed the meta-analyses and the drawings, ZP polished all the drawings. The first draft of the manuscript was jointly completed by FS, GW, WX, ZP, YX and YZ. NX, KH and ZH have revised and polished the first draft. RC and YC supervised and supported the whole process of writing the article. Finally, WX completed the submission work. All the authors made great contributions to the article.

Acknowledgments

Thanks to all authors for their contributions to this manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References

Bray, J. H., Foster-Davies, H., Salem, A., Hoole, A. L., Obad, D. R., Hakon, J. P. J., et al. (2021). Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 23 (8), 1802–1822. doi:10.1111/dom.14399

Budnitz, D. S., Lovegrove, M. C., Shehab, N., and Richards, C. L. (2011). Emergency hospitalizations for adverse drug events in older Americans. N. Engl. J. Med. 365 (21), 2002–2012. doi:10.1056/NEJMsa1103053

Cao, Y. (2007). Clinical Research on Multiple factor intervention of improving the insulin resistance. Master’s thesis. China: Shandong Traditional Chinese Medicine University. (In Chinese) doi:10.7666/FD1144281

Chang, W., Chen, L., and Hatch, G. M. (2015). Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies. Biochem. Cell Biol. 93 (5), 479–486. doi:10.1139/bcb-2014-0107

Chang, Y. C., Lin, C. J., Huo, Y. H., Chang, Y. H., Liu, S. J., and Hsu, H. Y. (2020). Therapeutic effects of beg vaccination on type 1 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. J. Diabetes Res. 2020, 6954125. doi:10.1155/2020/6954125

Di Pparro, F., Villanova, N., Agostini, F., Marinossi, R., Soverini, V., and Marchesini, G. (2012). Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. Diabetes Metab. Syndr. Obes. 5, 213–217. doi:10.2147/dmso.S33718

Dong, H., Wang, N., Zhao, L., and Lu, F. (2012). Berberine in the treatment of type 2 diabetes mellitus: A systematic review and meta-analysis. Evid. Based. Complement. Altern. Med. 2012, 591654. doi:10.1155/2012/591654

Dong, K. L., Shang, J. J., and Tao, L. (2017). Effect of berberine combined with metformin on serum inflammatory factors and islet function in type 2 diabetes mellitus. J. Clin. pathology 37 (07), 1418–1422. (In Chinese).

Drazen, B., Arodà, V. R., Barikis, G., Benson, G., Brown, F. M., Freeman, R., et al. (2022). 6. Glycemic targets: Standards of medical care in diabetes-2022. Diabetes Care 45 (1), 583–596. doi:10.2337/dci22-0056

Fan, C., Li, Y., Song, H. P., and Wang, Q. (2018). Effectiveness evaluation analysis on berberine combination with metformin treating type 2 diabetes. Med. Hosp. 18 (5), 731–733. (In Chinese). doi:10.3969/j.issn.1671–332X.2018.05.033

Finol-Urdaneta, R. K., Remedi, M. S., Raasch, W., Becker, S., Clark, R. B., Stassinos, G. L., and Isbister, G. K. (2016). Treatment of sulfonylurea and insulin overdose. Acta Pharmacol. Sin. 37 (07), 1418–1422. (In Chinese).

Guo, J., Chen, H., Zhang, X., Lou, W., Zhang, P., Qiu, Y., et al. (2021). The effect of berberine on metabolic profiles in type 2 diabetic patients: A systematic review and meta-analysis of randomized controlled trials. Oxid Med. Cell Longev. 2021, 2074610. doi:10.1155/2021/2074610

Hou, K. A.-O., Wu, Z. X., Chen, X. Y., Wang, J. Q., Zhang, D., Xiao, C., et al. (2015). Berberine as a therapy for type 2 diabetes mellitus (damp-heat type). Chin. J. Inf. TCM 15 (03), 37–46. (In Chinese). doi:10.2174/1871105015666141617

Huang, J., Meng, W., and Li, M. L. (2008). Clinical observation of berberine combined with glipizide on type 2 diabetes. J. Clin. Res. 24 (2), 34–35. (In Chinese).

Liao, M., and Hao, Y. R. (2020). Action mechanism of berberine on diabetes mellitus and its complications. Mod. Recupititate 26 (13), 2637–2642. (In Chinese).

Lipton, J. J., Venker, C. E., Slatter, W. J., Reitma, W. D., and Van Haeften, T. W. (1997). Effect of glibenclamide on insulin release at moderate and high blood glucose levels in normal man. Eur. J. Clin. Invest. 27 (8), 685–689. doi:10.1046/j.1365–2362.1997.1710716.x

Liu, H. Y., and Hu, Q. M. (2008). Effect of berberine on islet p-cell function in type 2 diabetes mellitus(damp-heat type). Chin. J. Inf. TCM 15 (03), 12–14. (In Chinese).

Liu, L. F. (2004). Effect of berberine in adjuvant treatment of type II diabetes mellitus. J. Sichuan Traditional Chin. Med. 23 (02), 46. (In Chinese).

Liu, Z. M. (2013). Effect of metformin combined with berberine in the treatment of incipient type 2 diabetes mellitus. zhejiang J. Integr. traditional Chin. West. Med. 23 (05), 380–382. (In Chinese).

Lv, W., Wang, X., Xu, Q., and Lu, W. (2020). Mechanisms and characteristics of sulfonylureas and glinides. Curr. Top. Med. Chem. 20 (1), 37–56. doi:10.2174/156802662066191224141617

Nagy, L., Marton, J., Vida, A., Kun, S., et al. (2018). Glycogen phosphorylase inhibition improves beta cell function. Br. J. Pharmacol. 175 (2), 301–319. doi:10.1111/bph.13819

Praltey, R. E., and Weyer, C. (2001). The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 44 (8), 929–945. doi:10.1007/s001250100580

Rashidi, H., Namjoyan, F., Mehraban, Z., Zakerkish, M., Ghaderian, S. B., and Fathi, H. (2018). The effects of active ingredients of barberry root (berberine) on inflammatory factors in patients with type 2 diabetes mellitus. Eur. J. Clin. Investig. 48 (7), 855–861. doi:10.1111/eci.13155

Sheng, Z. X. (2009). The level of serum inflammatory factors in patients with T2DM and the impact of intervention after Berberine treatment. Master’s thesis. China: Sun Yat-sen University. (In Chinese).

Sun, H., Sareed, K., Karuranga, S., Pinknepank, M., Ogurtsova, K., Duncan, B. N., et al. (2022a). IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 183, 109119. doi:10.1016/j.diabres.2021.109119
Sun, H. Z., Lei, S. H., Gong, Y. C., and Yao, L. H. (2022b). Regulation of ion channels on insulin secretion in islet β cells. *Life Sci. Res.* 26 (10), 59–66. (In Chinese). doi:10.16605/j.cnki.1007-7847.2020.11.026

Sun, S. P. (2017). Effect of Berberine on the serum levels of IL-10, IL-6 and CRP in patients with type 2 diabetes mellitus. *J. Changchun Univ. Chin. Med.* 33 (03), 431–433. (In Chinese).

Tokajuk, A., Krzyzanowska-Grycel, E., Tokajuk, A., Grycel, S., Sadowska, A., and Car, H. (2015). Antidiabetic drugs and risk of cancer. *Pharmacol. Rep.* 67 (6), 1240–1250. doi:10.1016/j.pharep.2015.05.005

Tong, R. C. (2019). Study on hypoglycemic and hypotensive effects and mechanisms of total glycosides of Plantaginis semen. Doctoral thesis. China: Shanghai University of Chinese Medicine. (In Chinese). doi:10.27320/d.cnki.gzyys.2019.000006

Wang, W. (2008). Effect of berberine on blood glucose, blood lipid and serum leptin of primary type 2 diabetes mellitus patients. Master’s thesis. China: Shandong Traditional Chinese Medical University. (In Chinese).

Wei, C., and Deng, X. G. (2021). Effect of berberine combined with metformin and acarbose in the treatment of newly diagnosed type 2 diabetes mellitus. *Contemp. Med. Symp.* 19 (11), 139–146. (In Chinese). doi:10.3969/j.issn.2095-7629.2021.11.084

Wu, Q. H., Li, B. T., and Tu, J. (2019). Compound traditional Chinese medicine in treatment of diabetes. *J. Chin. Materia Medica* 44 (6), 1104–1109. (In Chinese). doi:10.19540/j.cnki.cjcmm.20181212.001

Wu, M., Yang, S., Wang, S., Cao, Y., Zhao, R., Li, X., et al. (2020). Effect of berberine on atherosclerotic and gut microbiota modulation and their correlation in high-fat diet-fed ApoE−/− mice. *Front. Pharmacol.* 11, 223. doi:10.3389/fphar.2020.00223

Xiang, W., Huang, X. J., and Huang, G. X. (2011). A study of two anti-inflammatory drugs in patients with incipient type 2 diabetes. *J. Pract. DIABETOLOGY* 07 (2), 51–52. (In Chinese).

Xing, Y., Liu, X., Lin, Y., and Zhang, Y. (2017). Progress in pharmacological effects and clinical applications of berberine. *Chin. J. Pharmacol. Toxicol.* 31 (6), 491–502. (In Chinese). doi:10.3867/issn.1001-0408.2017.06.001

Xu, F. J. (2008). Effects of berberine and pignosterone oil type 2 diabetes acute insulin secretion and adiponectin. *Hainan Med.* 19 (5). (In Chinese).

Xue, S. X., Xu, J. Q., and Tie, L. L. (2012). Effectiveness of sulfonylureas combined with berberine metformin in the treatment of diabetes. *Shanghai J. Tradit. Chin. Med.* 33 (10), 1335–1336. (In Chinese).

Yang, D. (2008). Effect on different model intervention of improving the 2 diabetes insulin resistance. Master’s thesis. China: Shandong Traditional Chinese Medicine University. (In Chinese). doi:10.7666/d.D459316

Yang, L. (2010). Clinical observation of berberine hydrochloride combined with acarbose in the treatment of type 2 diabetes. *Chin. J. Prim. Med. Pharm.* 24, 3422–3423. (In Chinese).

Yang, S. N., Shi, Y., Yang, G., Li, Y., Yu, J., and Berggren, P. O. (2014). Ionic mechanisms in pancreatic β cell signaling. *Cell. Mol. Life Sci.* 71 (21), 4149–4177.

Yang, X., Liu, Z. M., and Yang, H. J. (2020). Clinical study of berberine hydrochloride tablets combined with metformin in the treatment of incipient type 2 diabetes mellitus. *Shanghai J. Traditional Chin. Med.* 54. (In Chinese).

Yao, J. R., and Xie, D. H. (2015). Clinical observation of triple therapy in the treatment of type 2 diabetes mellitus. *China Pharm.* 29, 4107–4109. (In Chinese). doi:10.6039/j.cnki.1001-0408.2015.29.26

Yao, X. G., Chen, F., Li, P., Quan, L., Chen, J., Yu, L., et al. (2013). Natural product vindoline stimulates insulin secretion and efficiently ameliorates glucose homeostasis in diabetic murine models. *J. Ethnopharmacol.* 150 (1), 285–297. doi:10.1016/j.jep.2013.08.043

Ye, L. N. (2021). Analysis of the value of sulfonylureas and berberine metformin in the treatment of diabetes. *Living Sci.* 24 (10), 263. (In Chinese). doi:10.3969/j.issn.1672-9714.2021.18.263

Ye, W. P. (2010). Clinical efficacy of berberine treatment of diabetes. *Med. Hosp.* 10 (8), 9–10. (In Chinese).

Yin, S. L. (2011). Effects of berberine hydrochloride on blood glucose, insulin and blood lipid in newly diagnosed type 2 diabetes mellitus. *Acta Acad. Med. Xuzhou* 31 (1), 40–41. (In Chinese).

You, S., and Liu, B. (2007). Clinical observation on the effect of berberine on urinary type IV collagen in diabetic patients. *Chin. Hosp. Pharm. J.* 6, 793–795. (In Chinese).

Yu, J. W. (2020). Study on the effect of berberine hydrochloride combined with metformin on hypoglycemic effect and insulin function in patients with T2DM. Master’s thesis. China: Hangzhou Normal University. (In Chinese).

Zhang, H. (2017). Analysis of the value of sulfonylureas and berberine metformin in the treatment of diabetes. *DIABETES NEW WORLD* 20 (24), 82–83. (In Chinese).

Zhang, X. G., and Chen, R. X. (2017). Efficacy of sulfonylureas combined with berberine metformin in the treatment of diabetes. *Guidel. Health Care* 25, 252. (In Chinese).

Zhang, Y. D., and Yuan, X. (2012). Clinical observation of berberine in the treatment of type 2 diabetes. *J. HEZE Med. Coll.* 24 (02), 27–28. (In Chinese).

Zhang, Y., Li, X., Zou, D., Liu, W., Yang, J., Zhu, N., et al. (2008). Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. *J. Clin. Endocrinol. Metab.* 93 (7), 2559–2565. doi:10.1210/jc.2007-2404

Zhao, M. M., Lu, J. L., Li, S. W., Yang, W. H., Guo, J., et al. (2016). Geniposide acutely stimulates insulin secretion in pancreatic β-cells by regulating GLP-1 receptor/cAMP signaling and ion channels. *Mol. Cell. Endocrinol.* 430, 89–96. doi:10.1016/j.mce.2016.04.020

Zhou, Y., Liu, B., Wang, Y. G., Cao, X. R., Li, Q., et al. (2021). Berberine is an insulin secretagogue targeting the KCNHex potassium channel. *Nat. Commun.* 12 (1), 5616. doi:10.1038/s41467-021-25952-2

Zhou, R., Xiang, C. P., Zhang, J. J., and Yang, H. J. (2020). Research progress on chemical compositions of Coptidis Rhizoma and pharmacological effects of berberine. *China J. Chin. Materia Medica* 45 (19), 4561–4573. (In Chinese). doi:10.19540/j.cnki.cjcm.20200527.202

Zhu, G. C., Zhang, C. S., and Kang, S. K. (2009). Effect of berberine combined with metformin in the treatment of type II diabetes mellitus. *Chin. J. Misdiagn* 9 (4), 788–789. (In Chinese).

Zhu, J. X., Wang, X. Y., Lv, W. Q., and Li, X. Z. (2015). Gliclazide combined with berberine in the treatment of type 2 diabetes mellitus. *zhejiang J. Integ. traditional Chin. West. Med.* 25 (10), 915–917. (In Chinese).

Zhu, Y. Q., Jiang, H., Sha, W. J., and Lei, T. (2020). Effect of berberine on hypoglycemic effect and gut microbiota in patients with newly diagnosed type 2 diabetes mellitus. *J. TONGJI Univ. Sci.* 41 (04), 467–472. (In Chinese).